Episodi
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Scott Kirkland, CEO and Managing Director of EMVision Medical Devices.
EMVision (ASX:EMV) is an ASX listed, Australian med tech company focused on developing portable brain imaging devices using electromagnetic (EM) technology. It was spun out of University of Queensland in 2017 and had its IPO in late-2018.
EMVision’s primary product is a portable scanner designed to quickly and non-invasively detect and monitor neurological conditions like stroke.
Unlike traditional imaging methods such as CT or MRI, EMVision’s technology allows for bedside or on-the-go imaging, which can be particularly useful in emergency settings or in rural and remote locations to improve healthcare access.
Scott has a wealth of experience in the emerging tech both here and overseas, having previously been Head of Client Sales at Quantcast, a US-based technology company. He is also a member of the Australian Institute of Company Directors.
In this episode you will hear about:
How EMVision is using ultra high frequency radio signals to differentiate stroke types, with the aim of speeding up diagnosis and treatment particularly within the first hour post-onset of a strokeFindings from the 300-patient trial* conducted in Australia, and the company’s plans for a pivotal US trialLearnings from EMVision’s capital raising, which led to a AUD$15M investment from Keysight TechnologiesThe importance for startups to build strategic relationships early on and to utilise finite resources efficientlyScott’s advice for budding entrepreneurs and those seeking mentorship.
Learn more about Scott Kirkland and EMVision Medical Devices.
*EMVision released EMView study data subsequent to this recording, see ASX release ‘Algorithms deliver excellent results in EMView study’ 12th Nov.Updated version 05/08/22
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Justin Zenanko, co-founder, CEO and president of SynerFuse™, a medical device company based in the United States developing an innovative solution to reduce chronic back pain and improve patient quality of life.
Justin and his team have patented the SynerFuse e-TLIF™ procedure which aims to make traditional spine implant surgery more successful and cost effective by combining neuromodulation at the time surgeons are performing fusion back surgery. SynerFuse has completed a proof-of-concept study of 15 patients and they're coming up to a 12-month review of post-surgery results in October.A certified public accountant, Justin has experience in corporate finance, entrepreneurship and startup development. He has previously led fundraising efforts resulting in $68 million of investment, including $34 million in angel funding and 34 million in Series A funding from a strategic investor.
In this episode you will hear about:
The global need to address opioid dependency by developing innovative drug-free treatments for chronic painHow SynerFuse’s e-TLIF technology stimulates the dorsal root ganglion as part of spinal fusion surgery – a world-first approach How Justin and his co-founders overcame skepticism from specialists and the challenges of the COVID pandemic to get FDA approval on a feasibility study Why Justin has invested his own money into SynerFuse and his advice to other unconventional entrepreneurs.Learn more about SynerFuse and the e-TLIF procedure.
Updated version 05/08/22
-
Episodi mancanti?
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. SYNthesis BioVentures is a registered early-stage venture Capital Limited partnerships fund, focused on early-stage therapeutics investing in projects from discovery through preclinical proof of concept and IND enabling studies.
Amir and the team are investing in small molecule therapeutics, biologics and cell and gene therapies for conditions with significant unmet need. Their aim, to accelerate the development of cutting-edge therapies and technologies, ultimately improving patient outcomes and delivering value to their investors.
Along with a PhD in molecular biology and an MBA, Amir has an extensive background in healthcare and international operations experience, having previously been head of business development for BiondVax, CEO of Amorphical and SoluBest, and a healthcare investment manager at OneVentures.
In this episode you will hear about:
How SYNthesis BioVentures is supporting early-stage research, Opportunities to partner with overseas biotech firms and license underutilised, innovative therapies for western marketsThe challenges of financing biotech innovations, and the role of crossover funds in bridging early-stage investments with public markets The importance of smart collaboration, and the need for startups to assemble a varied and knowledgeable team.Learn more about SYNthesis BioVentures
Updated version 05/08/22
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Anne-Laure Puaux, inaugural CEO of WEHI Ventures and Head of Business Development at WEHI.
WEHI Ventures manages 66ten, a first of its kind pre-seed and seed strategic investment fund of $66 million, dedicated to ideas developed by or in collaboration with, WEHI. With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, 66ten is the largest internal pre-seed and seed fund created by an Australian medical research institute, established to bridge the gap between scientific discoveries and commercial viability.
Before joining WEHI, Anne-Laure worked in Europe, US, Asia and Australia as part of biotech companies and multinational pharmaceutical companies such as GSK. Through these roles, she gained extensive global experience designing, evaluating, negotiating, and closing deals between academic research institutions, biotech companies, private investors and large multinational companies. She has also completed a PhD in Immunology and an MBA.
In this episode you will hear about:
How WEHI Ventures is focusing on turning early-stage discoveries into commercial successes, and its strategic management approach to high-risk, high reward projects that may be too risky or too early-stage for traditional investorsThe importance of collaboration between academia and industry in translating early-stage discoveries into market-ready therapiesAnne-Laure’s insights into how Australia needs to strengthen its innovation ecosystem to catalyse biotech commercialisation The strategic importance of mentorship when opportunities to explore different career pathways may be limited.
Learn more about WEHI Ventures
Learn about Dr Anne-Laure PuauxUpdated version 05/08/22
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Megan Baldwin, Founder, Chief Innovation Officer and Executive Director of Opthea Limited.
Opthea limited is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases. They have a world class team of ophthalmology experts working to develop breakthrough therapies for those who suffer from retinal disease.
Megan has over 20 years of experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. With a PhD in medicine from the University of Melbourne, and having conducted her postdoctoral studies at Genentech, Megan joined Circadian Technologies Limited, now Opthea, in 2008 as Head of Preclinical R&D, and became Chief Executive in 2014. Today, she's a member of the Australian Institute for Company Directors, a board member of AusBiotech and serves on the boards of public and private companies.
In this episode you will hear about:
How Opthea is working to improve outcomes for patients with wet AMD. Insight into Opthea’s strategy for attracting investment in its early-stage research and beyond What Megan thinks Australia needs to do in order to support translation of Australian innovation Megan’s advice for seeking mentorship and the importance of looking outside of your network.Learn more about Opthea.
Read about Megan Baldwin.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Bronwyn Le Grice, CEO and Managing Director of ANDHealth.
Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy.
In 2017, she founded ANDHealth – which is now one of Australia’s leading health technology commercialisation organisations.
It’s flagship ANDHealth+ program has a successful track record in taking businesses to scale, with companies selected in the program raising over $150 million in dilutive and non-dilutive funding, creating 400+ jobs, undertaking 72 clinical studies and impacting over 700,000 patients over the past 6 years.
In this episode, you will learn more about:
How digital health technology could shape the future of health care.Opportunities digital health provides to increase efficiency of care.Advice for digital health companies thinking of being part of an incubator or accelerator.Some of the key challenges faced by Australia in building a world class digital health industry.Discover more about ANDHealth.
Read about Bronwyn Le Grice
Updated version 05/08/22
-
In this episode of Med Tech Talks, Robert Klupacs is joined by Alon Greenspan, Managing Partner at Mind Ventures.
Mind Ventures is touted as the world’s first mental health-focused for-profit venture fund. Seeded by the Black Dog Institute, Mind Ventures invests in scalable, evidence-based solutions across the mental health spectrum, from illness to well-being.
Alon has a wealth of international global tech M&A and venture capital experience, having previously worked at Jelix Ventures, Herzog Fox, and Arnold Bloch Liebler. With degrees in commerce and law, he is also an active angel investor and start-up advisor.
In this episode you will hear about:
The mission of Mind Ventures and the need for innovations in mental healthThe role of an angel investor and the benefits for founders in connecting with themAlon’s advice for start ups and building long term relationships as an entrepreneurLessons Alon has learned as an impact investor.Learn more about Mind Ventures
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Stephen Tomisich, Co-founder and CEO of Trajan Scientific and Medical.
Based in Melbourne, Trajan develops and manufactures analytical science instruments, devices and solutions for health care, as well as for food and environment analysis – the only company of its kind listed on the ASX.
Stephen has a strong acquisition strategy, having grown Trajan from a kitchen table concept in 2011 to a global collaborator. Over the last 13 years, Trajan has acquired twelve businesses across the US, Europe and Asia; developing Trajan’s key capabilities and product lines for emerging technologies.
In this episode, you will hear more about:
Trajan’s unique business model and approach to acquisitions How purpose, passion and an ‘all in’ mindset laid the foundations for global successWhy it’s important to be your own threat as an innovator Four books Stephen recommends entrepreneurs read.Learn more about Trajan Scientific and Medical.
Stephen is a panellist at the upcoming Bionics Institute Innovation Lecture on 29 May in Melbourne. Learn more about the event and register your interest in attending.Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Chris Smith, a partner at Brandon Capital - Australasia's leading life science venture capital firm.
Chris has extensive experience in the global biotech industry. With a PhD in immunology and an MBA specialising in innovation and entrepreneurship from the University of Cambridge; he has also previously been a business development manager with CSL; and is currently a Director of Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera and Axelia Oncology, just to name a few.
In this episode, you will hear more about:
Tips for pitching to investors and building a relationship with venture capital firmsDemystifying the role of a VC in research and developmentBrandon Capital’s incubator approach to risk and investing in early-stage innovations.Learn about Dr Chris Smith
Visit the Brandon Capital website
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Steve Wesselingh, CEO of the National Health and Medical Research Council (NHMRC).
An infectious disease physician and researcher in HIV vaccine development and the impact of the microbiome on human health, Steve has a wealth of medical experience, clinical leadership, and national and international success.
The NHMRC is Australia's lead agency, driving innovative health and medical research to improve the health of all Australians.
Along with providing an ethical framework for health and medical research in our country, the NHMRC supports the discovery of new knowledge and its translation into public health, health services and medical products to improve health outcomes for all Australians.
In this episode you will hear about:
Steve’s journey to becoming one of the world’s leading HIV researchers.The influence international experience in the US and Papua New Guinea had on his careerFunding opportunities that could help Australia improve med tech or clinical outcomesSteve’s priorities as CEO of the NHMRC over the next 24 months and beyond, including government strategy input, and working more closely with the Australian Centre for Disease Control (CDC)Learn more about Professor Steve Wesselingh
Read more about the NHMRC.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Dean Freestone, Co-Founder of Seer Medical.
A modern Australian innovation success story, Seer Medical was founded in 2017 and specialises in the early detection and diagnosis of epilepsy.
The company has developed a highly innovative, portable video-EEG-ECG recording system that patients can take home with them, rather than being limited to hospital use.
Dr Freestone was one of three co-founders of Seer and was CEO until 2023. Today, he holds a board position at Seer Medical.
In this episode you will hear about:
Dean’s unique journey from his school days all the way to being Co-Founder at Seer Medical. How Seer Medical provides revolutionary new care and patient monitoring practices for patients with epilepsy. The sacrifices and challenges Dean faced on the commericalisation journey to make Seer Medical a success.Learn more:
Learn more about Dr Dean Freestone.
Find out more about Seer Medical.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by the Honourable Jaala Pulford, Chair of MTPConnect, Vice Chancellor’s Fellow at the University of Melbourne, and former Minister of the Parliament of Victoria.
Jaala is well known for her career in public service where she has held several significant portfolios, including Minister for Agriculture, Minister for Small Business and Minister for Innovation, Medical Research and the Digital Economy.
In her role as Minister for Innovation, Medical Research and the Digital Economy, Jaala was at the forefront of agendas to boost Victoria’s innovation ecosystem including the $2 billion Breakthrough Victoria Fund and the securing of both Moderna and BioNTech vaccines for Melbourne.
In this episode you will hear about:
Jaala’s career as a politician and her journey from Castlemaine, Victoria to the being a Minister in the Victorian Parliament. Insights into her time as Minister for Innovation, Medical Research and the Digital Economy which coincided with the COVID-19 pandemic. Her mission as Chair of MTPConnect and her thoughts on how Australia can improve its innovation ecosystem.Learn more:
Learn more about Jaala Pulford.
Find out more about MTPConnect.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Associate Professor Fiona Brownfoot, specialist obstetrician at the Mercy Hospital for Women, clinician scientist at the University of Melbourne and Co-Founder of Kali Healthcare.
Kali Healthcare is undergoing an exciting commericalisation journey and aims to transform pregnancy monitoring through the development of a wearable device that will allow expecting mothers to monitor foetal heartbeats at home.
In her role as Associate Professor of Obstetrics at the University of Melbourne, she heads the Obstetric Diagnostics and Therapeutics Group – a multidisciplinary team of scientists and engineers focused on developing new treatments for obstetric conditions – whilst mentoring PhD students to become the next generation of clinician scientists.
How Kali Heathcare aims to improve foetal monitoring with new portable, wearable technology in order to detect and prevent pregnancy complications The commericalisation journey of Kali Healthcare Fiona’s thoughts on the power of mentorship to propel the next generation of clinician scientists.
In this episode you will hear about:More information:
Learn more about Associate Professor Fiona Brownfoot.
Read more about Kali Healthcare.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Devinder Chauhan, a highly respected retinal ophthalmologist and Founding CEO of Macuject.
Macuject is a digital health company that harnesses AI to provide imaging and data solutions for ophthalmologists to them make clinical decisions when treating age-related macular degeneration.
Dr Chauhan founded Macuject in 2017 and is currently making the transition from clinician to entrepreneur as he and his team aim to roll this product out in eye clinics both domestically and internationally to improve visual outcomes for patients worldwide.
Devinder’s career as a retinal ophthalmologist and why he founded Macuject How Macuject aims to transform the treatment of age-related macular degeneration The lessons Devinder has learned as he moved from the clinic to become an entrepreneur.
In this episode you will hear about:More information:
Learn more about Dr Devinder Chauhan.
Read more about Macuject.
Updated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Andrew Wilks and Dr Chris Burns.
The journey of momelotinib from bench top to a commercial productProfessor Wilks and Dr Burns' experience as entrepreneursWhere momelotinib is today and the legacy of the Australian research effort.
Professor Wilks and Dr Burns are two research leaders who were involved in the incredible breakthrough of the drug, Momelotinib, which has emerged as a treatment for myelofibrosis – a rare type of bone marrow cancer.
In this episode you will hear about:More information:
Learn more about Professor Andrew Wilks
Find out more about Dr Chris BurnsUpdated version 05/08/22
-
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Moira O'Bryan, Dean of the Faculty of Science at the University of Melbourne.
Moira's journey to becoming Dean of the Faculty of Science at the University of MelbourneCould the male contraceptive pill be a reality?Her thoughts on how the University of Melbourne can be a leader in innovation for Australia.
Professor O'Bryan specialises in andrology and through her impressive research career, she has recently been given the prestigious role of a Dean at the Unversity of Melbourne which is ranked as the 14th best preforming university in the world per the QS rankings.
In this episode you will hear about:More information:
Learn more about Professor Moira O'Bryan.
Visit the University of Melbourne website.Updated version 05/08/22
-
In the latest episode of Med Tech Talks, we present a special keynote speech from Dr Andres Fouras, Founding CEO of 4DMedical, recorded at the Bionics Institute 2023 Innovation Lecture.
Dr Andreas Fouras and his team have developed a unique respiratory imaging system, which aims to change the outcome for patients with lung disease.
In 2012, Andreas founded 4DMedical to commercialise the technology, which is now an ASX listed company.
In his keynote, Andreas illustrates his entrepreneurial journey, speaks about the highly innovative technology at 4DMedical and shares some of his thoughts about innovation in Australia
Over 320 guests comprising med tech executives, researchers, clinicians, government staff and investors attended the Bionics Institute 2023 Innovation Lecture to explore how Australia can accurately measure innovation, boost the med tech ecosystem and strengthen connections.
More information:
Watch the Bionics Institute 2023 Innovation Lecture recording
Visit the 4DMedical website -
In the latest episode of Med Tech Talks, we present a special keynote speech from Kylie Walker, CEO of the Australian Academy of Technological Sciences and Engineering (ATSE), recorded at the Bionics Institute 2023 Innovation Lecture.
As CEO of ATSE, Kylie specialises in connecting technologists, engineers and scientists with governments, business, media and society with skills built over many years in senior federal communication and advocacy roles in science, technology and health sectors.
In her keynote, Kylie talks about using metrics to unlock the potential of Australian research and development, and the impact measuring innovation could have for the med tech sector.
Over 320 guests comprising med tech executives, researchers, clinicians, government staff and investors attended the Innovation Lecture to explore how Australia can accurately measure innovation, boost the med tech ecosystem and strengthen connections.
More information:
Watch the Bionics Institute 2023 Innovation Lecture recording
Visit the ATSE website -
In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Anne Kelso AO, CEO of the National Health and Medical Research Council (NHMRC).
At NHMRC, Anne’s key focus areas have been the restructure of the organisation’s grant program, developments in NHMRC’s peer review processes, and progressing initiatives to improve gender equity in health and medical research.
The role of the NHMRC in the Australian research ecosystem.Professor Kelso discussing some of the highlights of her career and the lessons she has learnt. Some of the mentors she has had on her journey, including legendary Australian scientists Professor Sir Gustav Nossal AC and the late Professor Donald Metcalf AC.
This year, Anne will be stepping down as CEO of NHMRC after eight years. .
In this episode, you will hear about:Learn more about:
The NHMRCProfessor Anne KelsoUpdated version 05/08/22
-
In this episode of Med Tech Talks, Robert Klupacs is joined by one of Australia’s most successful med tech expats, Dr Jeremy Buzzard, CEO of Enteralia Bioscience and co-founder of Induction Bio.
Jeremy also notably was a partner at McKinsey and Co., where he led the firm’s global healthcare strategy and corporate finance practice.
The missions of Enteralia Biosciences and Induction BioJeremy's reflections on his time at Harvard University and McKinsey and Co. His thoughts on the key learnings Australia can take from the US med tech market to improve our innovation outcomes.
Jeremy is on the record as being involved in more than 25 major transactions that were executed with an aggregate value of $56Bn USD.
In this episode, you will hear about:Learn more about:
Enteralia BiosciencesUpdated version 05/08/22
- Mostra di più
